• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Agilent Technologies Inc. (Amendment)

    4/10/24 2:03:52 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $A alert in real time by email
    SC 13G/A 1 tv0020-agilenttechnologiesin.htm SCHEDULE 13G/A agilenttechnologiesinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 10)*

    Name of issuer:  Agilent Technologies Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  00846U101

    Date of Event Which Requires Filing of this Statement: March 28, 2024

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  00846U101

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    382,331

    7.  SOLE DISPOSITIVE POWER

    28,605,698

    8.  SHARED DISPOSITIVE POWER

    1,276,764

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    29,882,462

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.20%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Agilent Technologies Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    5301 Stevens Creek Boulevard
    Santa Clara, CA 95051

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    00846U101

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  April 10, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $A alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $A

    DatePrice TargetRatingAnalyst
    2/10/2025$135.00 → $145.00Underweight → Equal Weight
    Barclays
    8/28/2024$157.00Overweight
    Wells Fargo
    7/10/2024$135.00 → $150.00Neutral → Buy
    Citigroup
    6/27/2024Outperform → Peer Perform
    Wolfe Research
    6/3/2024$135.00Hold
    Jefferies
    4/5/2024$145.00 → $163.00Hold → Buy
    Stifel
    12/13/2023$140.00Outperform
    Wolfe Research
    12/12/2023$130.00 → $133.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $A
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Mcdonnell Padraig sold $226,900 worth of shares (2,000 units at $113.45), decreasing direct ownership by 5% to 35,448 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    8/4/25 4:15:32 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    V.P., Corporate Controller Gonsalves Rodney was granted 9,031 shares, increasing direct ownership by 41% to 30,972 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    7/18/25 2:43:11 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Senior Vice President Dimarco Bret covered exercise/tax liability with 141 shares, decreasing direct ownership by 3% to 5,475 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    7/7/25 4:04:41 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Shane Snyder to Lead New Agilent Center of Excellence at Georgia Tech Focused on Water and the Environment

    Center of Excellence will feature bio-environmental research to facilitate advancements in environmental health and safety Agilent Technologies Inc. and Georgia Tech today announced the establishment of an Agilent Center of Excellence (CoE) for Environmental Health and Engineering to advance research in environmental sustainability, water recycling, and biologics. Internationally recognized environmental scientist Professor Shane Snyder from the School of Civil and Environmental Engineering at Georgia Tech will lead the Agilent CoE. The CoE will foster collaboration and innovation among researchers, serve as a hub for innovation in environmental characterization, and integrate Agilent's

    8/13/25 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Expands the Dako Omnis Family with Three New Models to Meet Evolving Pathology Lab Needs

    Agilent Technologies Inc. (NYSE:A) today announced the introduction of its Dako Omnis family of instruments with three new models—Agilent Dako Omnis 110, 165, and 165 Duo—designed to meet the evolving needs of pathology laboratories of all sizes. These new instruments provide labs with the flexibility to tailor their staining solutions according to volume, workflow, and diagnostic requirements. With the launch of the Agilent Dako Omnis family, Agilent transitions beyond a one-size-fits-all model to offer a tailored portfolio—empowering labs to select the configuration that best meets their needs. Scalable Solutions for Every Lab—From Routine to Revolutionary. Dako Omnis 110: Built fo

    8/4/25 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent to Announce Third-Quarter Fiscal Year 2025 Financial Results on Aug. 27

    Following an announcement earlier this week, Agilent Technologies Inc. (NYSE:A) confirms it will release financial results for the third quarter of fiscal year 2025 after the stock market closes on Wednesday, Aug. 27. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innova

    7/17/25 4:30:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    SEC Filings

    View All

    Amendment: Agilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    8/8/25 4:15:28 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 8-K filed by Agilent Technologies Inc.

    8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    7/15/25 8:43:34 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 144 filed by Agilent Technologies Inc.

    144 - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    7/1/25 12:45:28 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Agilent upgraded by Barclays with a new price target

    Barclays upgraded Agilent from Underweight to Equal Weight and set a new price target of $145.00 from $135.00 previously

    2/10/25 6:55:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Wells Fargo initiated coverage on Agilent with a new price target

    Wells Fargo initiated coverage of Agilent with a rating of Overweight and set a new price target of $157.00

    8/28/24 7:20:29 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent upgraded by Citigroup with a new price target

    Citigroup upgraded Agilent from Neutral to Buy and set a new price target of $150.00 from $135.00 previously

    7/10/24 7:22:08 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gonsalves Rodney (Amendment)

    4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    10/20/23 1:07:25 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    9/29/23 4:03:46 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Leadership Updates

    Live Leadership Updates

    View All

    Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025

    Agilent Technologies Inc. (NYSE:A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions that enable simultaneous DNA and methylation profiling from a single sample, the Avida product portfolio has expanded to include three new DNA panels*. Optimized based on the requirements of the European OncNGS Consortium, these catalog p

    4/24/25 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent to Acquire North American CDMO BIOVECTRA

    Expands Agilent's end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing Agilent Technologies Inc. (NYSE:A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722078870/en/A BIOVECTRA manufacturing facility (Photo: Business Wire) Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. The acquisition builds on Agilent's CDMO specializati

    7/22/24 9:01:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

    Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

    6/26/24 8:00:00 AM ET
    $A
    $ANIK
    $AVNT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical/Dental Instruments
    Health Care

    $A
    Financials

    Live finance-specific insights

    View All

    Agilent to Announce Third-Quarter Fiscal Year 2025 Financial Results on Aug. 27

    Following an announcement earlier this week, Agilent Technologies Inc. (NYSE:A) confirms it will release financial results for the third quarter of fiscal year 2025 after the stock market closes on Wednesday, Aug. 27. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innova

    7/17/25 4:30:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Announces CFO Transition

    Agilent Technologies Inc. (NYSE:A) today announced that effective July 31, Senior Vice President and Chief Financial Officer Bob McMahon will step down from his role as he relocates to the East Coast for family reasons and prepares for the next chapter in his career. Following McMahon's departure, Rodney Gonsalves, Agilent's current corporate controller and principal accounting officer, will additionally serve as interim CFO until McMahon's successor is named. "I want to sincerely thank Bob for his seven impactful years of service at Agilent. His leadership and contributions have played an important role in our company's growth, and we wish him the best in his future endeavors," said Pr

    7/15/25 8:30:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Reports Second-Quarter Fiscal Year 2025 Financial Results

    Agilent delivers strong quarter, enabled by Ignite Transformation Highlights Revenue of $1.67 billion for the second quarter ended April 30, 2025, representing growth of 6.0% reported and up 5.3% on a core(1) basis compared with the second quarter of 2024. GAAP net income of $215 million; earnings per share (EPS) of $0.75, down 29% from the second quarter of 2024. Non-GAAP(2) net income of $373 million; EPS of $1.31, up 7% from the second quarter of 2024. Outlook for full 2025 fiscal year and Q3 Full-year revenue outlook is now in the range of $6.73 billion to $6.81 billion, representing a range of up 3.4% to 4.6% reported, while maintaining 2.5% to 3.5% core(1). Non-GAAP E

    5/28/25 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 1:27:37 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 11:54:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/4/24 10:57:57 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials